144 related articles for article (PubMed ID: 30889498)
1. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
Veerman GDM; Lam MH; Mathijssen RHJ; Koolen SLW; de Bruijn P
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1113():37-44. PubMed ID: 30889498
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
3. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Mukai Y; Wakamoto A; Hatsuyama T; Yoshida T; Sato H; Fujita A; Inotsume N; Toda T
Ther Drug Monit; 2021 Dec; 43(6):772-779. PubMed ID: 33871406
[TBL] [Abstract][Full Text] [Related]
4. An UPLC-MS/MS method for the quantitation of alectinib in rat plasma.
Huang XX; Li YX; Li XY; Hu XX; Tang PF; Hu GX
J Pharm Biomed Anal; 2017 Jan; 132():227-231. PubMed ID: 27768922
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.
van Veelen A; van Geel R; Schoufs R; de Beer Y; Stolk LM; Hendriks LEL; Croes S
Biomed Chromatogr; 2021 Dec; 35(12):e5224. PubMed ID: 34363425
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma.
Zheng X; Wang W; Zhang Y; Ma Y; Zhao H; Hu P; Jiang J
Biomed Chromatogr; 2018 Dec; 32(12):e4365. PubMed ID: 30119142
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS.
de Leeuw SP; de Bruijn P; Koolen SLW; Dingemans AC; Mathijssen RHJ; Veerman GDM
J Pharm Biomed Anal; 2023 Feb; 225():115233. PubMed ID: 36638566
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
[TBL] [Abstract][Full Text] [Related]
9. Determination of intracellular anlotinib, osimertinib, afatinib and gefitinib accumulations in human brain microvascular endothelial cells by liquid chromatography/tandem mass spectrometry.
Ma Z; Lu S; Zhou H; Zhang S; Wang Y; Lin N
Rapid Commun Mass Spectrom; 2021 Jan; 35(1):e8955. PubMed ID: 32990383
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry.
Zhou Y; Liu M; Jiang J; Wang H; Hu P
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():59-66. PubMed ID: 24099858
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Aghai-Trommeschlaeger F; Zimmermann S; Gesierich A; Kalogirou C; Goebeler ME; Jung P; Pelzer T; Kurlbaum M; Klinker H; Isberner N; Scherf-Clavel O
Clin Biochem; 2022; 105-106():35-43. PubMed ID: 35483452
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.
Rood JJM; van Bussel MTJ; Schellens JHM; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1031():80-85. PubMed ID: 27469903
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study.
Huang Y; Zheng S; Pan Y; Li T; Xu ZS; Shao MM
J Pharm Biomed Anal; 2016 Sep; 128():184-190. PubMed ID: 27262994
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
15. An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats.
Dong ST; Li Y; Yang HT; Wu Y; Li YJ; Ding CY; Meng L; Dong ZJ; Zhang Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30404182
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Rapid and Sensitive LC-MS/MS Method for the Pharmacokinetic Study of Osimertinib in Rats.
Xiong S; Deng Z; Sun P; Mu Y; Xue M
J AOAC Int; 2017 Nov; 100(6):1771-1775. PubMed ID: 28534470
[TBL] [Abstract][Full Text] [Related]
18. Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS).
Zhao Z; Pu Q; Sun T; Huang Q; Tong L; Fan T; Kang J; Chen Y; Zhang Y
Anticancer Agents Med Chem; 2024 Apr; ():. PubMed ID: 38584556
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study.
Ezzeldin E; Iqbal M; Herqash RN; ElNahhas T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1136():121851. PubMed ID: 31812004
[TBL] [Abstract][Full Text] [Related]
20. Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.
van Veelen A; van Geel R; de Beer Y; Dingemans AM; Stolk L; Ter Heine R; de Vries F; Croes S
Biomed Chromatogr; 2020 Apr; 34(4):e4771. PubMed ID: 31808583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
